Drugs / MHS552
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05272059 | Sep 2023 → Apr 2025 | type 1 diabetes mellitus | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05203419 | Mar 2022 → Jun 2023 | systemic lupus erythematosus | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHS552 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05272059 ↗ |
| Route | Subcutaneous | “administered once weekly as subcutaneous injection” NCT05203419 ↗ |